Theravance Biopharma Inc $ 19.45 0.69 (3.68%)
Volume:
378,997
Avg Vol (1m):
360,081
Market Cap $:
1.25 Bil
Enterprise Value $:
1.63 Bil
PE Ratio:
0.00
PB Ratio:
0.00
Financial Strength | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.43 | ||
| Equity-to-Asset | -0.65 | ||
| Debt-to-Equity | -2.23 | ||
| Debt-to-EBITDA | -2.91 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -4.47 | ||
| Beneish M-Score | -3.52 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -414.37 | ||
| Net Margin % | -386.9 | ||
| ROA % | -54.3 | ||
| ROC (Joel Greenblatt) % | -404.33 | ||
| 3-Year Revenue Growth Rate | 57.7 | ||
| 3-Year EBITDA Growth Rate | 9 | ||
| 3-Year EPS without NRI Growth Rate | 6.5 |
TBPH
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PS Ratio | 16.84 | ||
| EV-to-EBIT | -6.79 | ||
| EV-to-EBITDA | -7.04 | ||
| EV-to-Revenue | 22.75 | ||
| Current Ratio | 3.18 | ||
| Quick Ratio | 3.18 | ||
| Days Sales Outstanding | 80.6 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -14.75 |